Drug companies urged to improve R&D strategies

Share this article:

R&D strategies aimed at improving clinical success rates and lowering clinical study costs can help drug companies boost the flow of new prescription drugs, a new study said.
Tufts Outlook 2005 report found a new prescription medicine, on average costs $802 million and takes up to 15 years to develop and win FDA approval.
Investing in state-of-the-art information technology, to better understand data generated in discovery, and developing alliances with specialized drug developers remain two of the most promising routes available to drug companies to improve R&D productivity, the report indicated.
Other trends cited include:

-Steps to encourage industry to apply innovation to its manufacturing processes will play a major role in developing new prevention-oriented drugs and biologicals.

-Implementation of the Medicare Prescription Drug, Improvement and Modernization Act of 2003 will spur public and private efforts to quantify the costs and benefits of specific drugs.

-Rapidly rising prescription drug spending will increase pressure on drug developers to prove the cost effectiveness of their products to ensure reimbursement in private and public markets.

-Biotechnology firms are poised to prosper in the near-to-medium term due to their ability to field products with higher approval success rates.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions